SCHEMBL4674394

SCHEMBL4674394

O=C(C=C(O)c1nn[nH]n1)c1ccn(Cc2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.41
NCEH1 Q6PIU2 1/20 0.41
CYP2C19 P33261 1/20 0.38
KLKB1 P03952 1/20 0.37
ERCC5 P28715 1/20 0.37
FEN1 P39748 1/20 0.37
AKR1B1 P15121 1/20 0.34
MMEL1 Q495T6 1/20 0.34
NFE2L2 Q16236 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
PTGS1 P23219 1/20 0.33
AGTR1 P30556 1/20 0.33
AGTR2 P50052 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676260 0.91 MAP4K4 (0.34) CES1NCEH1CYP2C19KLKB1ERCC5
SCHEMBL4671844 0.90 CA12 (0.36) CES1NCEH1MMEL1CA12CA1
SCHEMBL4678580 0.90 KLKB1 (0.34) KLKB1AGTR1AGTR2
SCHEMBL4675184 0.90 KLKB1 (0.34) CES1NCEH1KLKB1ERCC5FEN1
SCHEMBL4679602 0.89 XDH (0.38) CES1NCEH1KLKB1ERCC5FEN1
SCHEMBL4673843 0.89 KDM4C (0.40) CES1NCEH1
SCHEMBL4674369 0.87 CYP19A1 (0.40) ERCC5FEN1
SCHEMBL4672087 0.86 KDM4C (0.39) CES1NCEH1ERCC5FEN1AKR1B1
SCHEMBL4679413 0.86 KDM4A (0.38) CES1NCEH1CYP2C19ERCC5FEN1
SCHEMBL5899369 0.82 CYP2C19 (0.38) CYP2C19KLKB1AKR1B1NFE2L2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
US-20030171406-A1 Medicinal compositions containing propenone derivatives SHIONOGI & CO., LTD (JP) 2003-09-11 US disclosed
EP-1295879-A1 MEDICINAL COMPOSITIONS CONTAINING PROPENONE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2003-03-26 EP disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885CYP2C19 53/4885
US-20030171406-A1 Medicinal compositions containing propenone derivatives RPL17, EBP, SERPINB1 CES1 1019/4885NCEH1 2553/4885CYP2C19 1646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.